Mark D. Matteucci

Cancer Clinic — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index6.2kcitations98works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA and Nucleic Acid Chemistry(61), Advanced biosensing and bioanalysis techniques(32), Cancer, Hypoxia, and Metabolism(25), RNA Interference and Gene Delivery(22), Synthesis and Characterization of Heterocyclic Compounds(13)

Publications98 total

Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Clinical Cancer Research·2024Open Access
Supplementary Methods, Tables 1-5, Figures 1-9 from Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
2023Open Access
Supplementary Methods, Tables 1-5, Figures 1-9 from Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
2023Open Access
Data from Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
2023Open Access
Data from Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
2023Open Access
Supplementary Figures 1-3 from Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
2023Open Access
Supplementary Figures 1-3 from Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
2023Open Access
Data from Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
2023Open Access
Data from Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
2023Open Access
Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models
Cancer Biology & Therapy·2016· 26 citedOpen Access
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
BMC Cancer·2015· 24 citedOpen Access
Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
PubMed·2015· 26 citedOpen Access
Abstract 1784: Enhancement of hypoxia-activated prodrug TH-302 activity by Chk1 inhibition
Cancer Research·2012
Abstract 3720: Combination treatment with hypoxia-activated prodrug TH-302 and the mTOR inhibitor everolimus results in enhanced antitumor efficacy in preclinical models
Cancer Research·2012
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Cancer Chemotherapy and Pharmacology·2012· 113 cited
Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Clinical Cancer Research·2011· 194 cited
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Molecular Cancer Therapeutics·2011· 203 cited
Abstract 535: Hypoxia-dependent in vivo activity of the hypoxia-activated prodrug (HAP) TH-302
Cancer Research·2011
Abstract 5054: Hypoxia-activated prodrug TH-302 enhances antitumor activity of antiangiogenics in preclinical models
Cancer Research·2011· 1 cited
Abstract 2648: Pharmacological modulation of TH-302-mediated <i>in vitro</i> cytotoxicity
Cancer Research·2011· 1 cited
page 1 of 5Next →

Frequent Co-authors

Brian C. Froehler(16), Richard W. Wagner(10), John F. Milligan(8), Charles P. Hart(6), Jessica D. Sun(5), Dharmendra Ahluwalia(5), Shalini Wadwani(5), Kuei‐Ying Lin(4), Robert J. Jones(4), Arnold J. Gutierrez(3), Courtney Moulds(3), W. Michael Flanagan(3), Fanying Meng(3), Deepthi Bhupathi(3), Damien Ferraro(3), Marvin H. Caruthers(3), Deborah Grant(3), Thomas R. Webb(3), Norbert Bischofberger(3), Jeffrey S. Pudlo(3)